CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.

1:16-cv-00987

Overview

Case Number 1:16-cv-00987
Filing Date 2016-10-24
Status Terminated
Termination Date 2017-12-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

4 Attorneys Listed

Phoebe M. Hung

Email: phung@wsgr.com

Nicole W. Stafford

Email: nstafford@wsgr.com

Mary Matterer

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800
Fax: +1 (302) 571-1750

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Plaintiff

Takeda Pharmaceuticals U.S.A., Inc. Operating Company

Represented By

7 Attorneys Listed

Ted G. Dane

Email: ted.dane@mto.com

Jeffrey I. Weinberger

Email: jeffrey.weinberger@mto.com

Heather E. Takahashi

Email: heather.takahashi@mto.com

Elizabeth A. Laughton

Email: elizabeth.laughton@mto.com

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Celia R. Choy

Email: Celia.Choy@mto.com

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 5 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (5 found):
U.S. Courts: 5
U.S. District Court 2023-11-06
1:23-cv-01264

Takeda Pharmaceuticals U.S.A., Inc. v. Scilex Pharmaceuticals Inc.

U.S. Family Sibling (["US7619004", "US7820681", "US7964648", "US8093297", "US8097655", "US8440722"])
Status: DED
U.S. District Court 2019-12-02
1:19-cv-02216

Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-02-27
1:14-cv-00268

Takeda Pharmaceuticals USA Inc. v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-08-30
1:13-cv-01524

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-04-04
1:12-cv-00419

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

16 Patents

There are 16 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7906519
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-08-18
Issued: 2011-03-15
Active (3.7 yrs remaining)
Expires: 2030-08-18
US7935731
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2010-05-25
Issued: 2011-05-03
Active (3.5 yrs remaining)
Expires: 2030-05-25
US8093298
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2011-05-18
Issued: 2012-01-10
Active (4.5 yrs remaining)
Expires: 2031-05-18
US7964648
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-01-15
Issued: 2011-06-21
Active (3.2 yrs remaining)
Expires: 2030-01-15
US8093297
Methods for concomitant administration of colchicine and a second active agent
Filed: 2011-04-22
Issued: 2012-01-10
Active (4.4 yrs remaining)
Expires: 2031-04-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

17

Dispositive

10

Granted

1

Denied

0

Pending / Review

13

Motions by Category

Procedural / Extension Motion 2 Motion to Dismiss 10 Claim Construction / Markman Filing 5

Key Dispositive Motions & Rulings

Motion to Dismiss Granted
MEMORANDUM ORDER: Defendant's request to dismiss or transfer (D.I. 50 ) is DENIED. The Motion to Dismiss the Declaratory Judgement Act Counts IV-XVII (D.I. 1...
Entry #63 • 2017-08-03 Document →
Motion to Dismiss Pending / Under Review
[SEALED] Reply in Further Support 10 Motion to Dismiss or Strike the Declaratory Judgment Act Counts IV through XVII for Improper Venue, filed by Mylan Pharmace...
Entry #59 • 2017-07-24 Document →
Motion to Dismiss Pending / Under Review
[SEALED] Opposition to 50 Supplemental Brief in Support of 10 Motion to Dismiss or Strike, filed by Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per...
Entry #56 • 2017-07-18 Document →
Motion to Dismiss Pending / Under Review
ORAL ORDER: Oral argument on the Motion to Dismiss or Strike the Declaratory Judgement Act Counts IV - XVII (D.I. 10 ) is now set for 7/27/2017, at 9:00 AM in C...
Entry #42 • 2017-06-16 Document →
Motion to Dismiss Pending / Under Review
REPLY BRIEF re 10 MOTION to Dismiss or Strike The Declaratory Judgement Act Counts IV - XVII, filed by Mylan Pharmaceuticals Inc.. (Matterer, Mary) Modified on ...
Entry #30 • 2017-03-06 Document →
Motion to Dismiss Pending / Under Review
ANSWERING BRIEF in Opposition re 10 MOTION to Dismiss or Strike The Declaratory Judgement Act Counts IV - XVII, filed by Takeda Pharmaceuticals U.S.A., Inc..Rep...
Entry #20 • 2017-01-19 Document →

Docket Entries

(126 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2018484.) - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Civil Cover Sheet)(nmg) (Entered: 10/25/2016)

Entry #1 • 2016-10-24
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 10/25/2016)

Entry #2 • 2016-10-24
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/19/2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/19/2019. (nmg) (Entered: 10/25/2016)

Entry #3 • 2016-10-24
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,906,519; 7,935,731; 8,093,298; 7,964,648; 8,093,297. (nmg) (Entered: 10/25/2016)

Entry #4 • 2016-10-24
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited, Corporate Parent Takeda Pharmaceuticals International AG for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (nmg) (Entered: 10/25/2016)

Entry #5 • 2016-10-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc